ADPT · Insider Trading
Adaptive Biotechnologies Corporation Common Stock
Every open-market purchase and sale reported by ADPT officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-11-06 | Julie Rubinstein | President and COO | MIXED | — | −$521.74K |
| 2026-11-03 | Julie Rubinstein | President and COO | MIXED | — | −$496.19K |
| 2026-10-29 | Julie Rubinstein | President and COO | MIXED | — | −$565.39K |
| 2026-10-26 | Julie Rubinstein | President and COO | MIXED | — | −$464.75K |
| 2026-10-21 | Julie Rubinstein | President and COO | MIXED | — | −$446.38K |
| 2026-10-16 | Julie Rubinstein | President and COO | MIXED | — | −$464.65K |
| 2026-10-13 | Julie Rubinstein | President and COO | MIXED | — | −$487.16K |
| 2026-10-08 | Susan Bobulsky | Chief Commercial Officer, MRD | Sell | −6,444 | −$193.32K |
| 2026-10-08 | Julie Rubinstein | President and COO | MIXED | — | −$515.52K |
| 2026-10-05 | Julie Rubinstein | President and COO | MIXED | — | −$581.62K |
| 2026-10-05 | Francis Lo | Chief People Officer | MIXED | — | −$576.14K |
| 2026-09-18 | Francis Lo | Chief People Officer | MIXED | −9,846 | −$2.23M |
| 2026-09-17 | Susan Bobulsky | Chief Commercial Officer, MRD | Sell | −1,195 | −$32.27K |
| 2026-09-02 | Katey Einterz Owen | Director | G | −12,539 | — |
| 2026-08-28 | Katey Einterz Owen | Director | Sell | −9,615 | −$249.99K |
| 2026-08-20 | Robert Hershberg | Director | MIXED | −15,664 | −$653.41K |
| 2026-08-19 | Peter M Neupert | Director | MIXED | −109,690 | −$3.04M |
| 2026-08-19 | Chad M Robins | CEO and Chairman | MIXED | — | −$10.95M |
| 2026-08-12 | Susan Bobulsky | Chief Commercial Officer, MRD | Sell | −3,000 | −$75.00K |
| 2026-08-03 | Susan Bobulsky | Chief Commercial Officer, MRD | Sell | −1,299 | −$31.18K |
| 2026-07-23 | Harlan S Robins | Chief Scientific Officer | MIXED | −207,600 | −$8.91M |
| 2026-07-20 | Susan Bobulsky | Chief Commercial Officer, MRD | Sell | −5,000 | −$115.00K |
| 2026-07-17 | Francis Lo | Chief People Officer | MIXED | — | −$1.45M |
| 2026-07-07 | Harlan S Robins | Chief Scientific Officer | Sell | −386,240 | −$8.50M |
| 2026-07-06 | Susan Bobulsky | Chief Commercial Officer, MRD | Sell | −487 | −$10.71K |
| 2026-07-06 | Francis Lo | Chief People Officer | MIXED | −20,221 | −$1.50M |
| 2026-06-29 | Susan Bobulsky | Chief Commercial Officer, MRD | Sell | −5,000 | −$102.50K |
| 2026-06-29 | Michelle Renee Griffin | Director | MIXED | — | −$644.80K |
| 2026-06-17 | Harlan S Robins | Chief Scientific Officer | Sell | −106,160 | −$1.85M |
| 2026-06-15 | Susan Bobulsky | Chief Commercial Officer, MRD | Sell | −5,000 | −$95.00K |
| 2026-06-08 | Susan Bobulsky | Chief Commercial Officer, MRD | Sell | −11,000 | −$198.00K |
| 2026-06-08 | Francis Lo | Chief People Officer | MIXED | −20,220 | −$522.27K |
| 2026-05-20 | Kyle Piskel | Chief Financial Officer | Sell | −3,115 | −$40.62K |
| 2026-04-29 | Julie Rubinstein | President and COO | MIXED | −4,330 | −$146.48K |
| 2026-04-24 | Julie Rubinstein | President and COO | MIXED | −13,014 | −$424.78K |
| 2026-04-21 | Julie Rubinstein | President and COO | MIXED | −13,014 | −$490.74K |
| 2026-04-16 | Julie Rubinstein | President and COO | MIXED | −13,014 | −$452.61K |
| 2026-04-13 | Julie Rubinstein | President and COO | MIXED | −13,014 | −$429.15K |
| 2026-04-10 | Francis Lo | Chief People Officer | MIXED | −20,220 | −$330.69K |
| 2026-04-10 | Harlan S Robins | Chief Scientific Officer | Sell | −10,000 | −$148.50K |
| 2026-04-08 | Chad M Robins | CEO and Chairman | Sell | −120,595 | −$1.77M |
| 2026-04-08 | Julie Rubinstein | President and COO | MIXED | −13,014 | −$525.18K |
| 2026-04-02 | Julie Rubinstein | President and COO | MIXED | −8,676 | −$339.64K |
| 2026-03-26 | Julie Rubinstein | President and COO | MIXED | −13,014 | −$481.15K |
| 2026-03-23 | Julie Rubinstein | President and COO | MIXED | −13,014 | −$461.99K |
| 2026-03-18 | Julie Rubinstein | President and COO | MIXED | −13,014 | −$472.92K |
| 2026-03-13 | Susan Bobulsky | Chief Commercial Officer, MRD | Sell | −41,338 | −$544.42K |
| 2026-03-13 | Francis Lo | Chief People Officer | Sell | −30,593 | −$430.75K |
| 2026-03-13 | Michelle Renee Griffin | Director | Sell | −15,394 | −$214.13K |
| 2026-03-13 | Kyle Piskel | Chief Financial Officer | Sell | −18,672 | −$245.91K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Chad M Robins | CEO and Chairman | 2,683,043 | $81.19M |
| Harlan S Robins | Chief Scientific Officer | 1,312,058 | $39.70M |
| Susan Bobulsky | Chief Commercial Officer, MRD | 389,350 | $11.78M |
| Julie Rubinstein | President and COO | 377,802 | $11.43M |
| Sharon Benzeno | Chief Commercial Ofc Imm Med | 272,751 | $8.25M |
| Kyle Piskel | Chief Financial Officer | 256,725 | $7.77M |
| Peter M Neupert | Director | 255,315 | $7.73M |
| Francis Lo | Chief People Officer | 242,065 | $7.32M |
| Robert Hershberg | Director | 77,347 | $2.34M |
| Michael J Pellini | Director | 69,690 | $2.11M |
| Katey Einterz Owen | Director | 66,100 | $2.00M |
| Michelle Renee Griffin | Director | 15,625 | $472.81K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ADPT quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.